NCT04710407View on ClinicalTrials.gov

Study to Assess the Intrapulmonary Pharmacokinetics of SPR859 by Comparing the Plasma, Epithelial Lining Fluid (ELF), and Alveolar Macrophages (AM) Concentrations Following the Oral Administration of Five Doses of SPR994 in Healthy, Nonsmoking Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

December 7, 2020

Primary Completion Date

March 10, 2021

Study Completion Date

March 10, 2021

Conditions
Healthy Volunteers
Interventions
DRUG

TBPM-PI-HBr

TBPM-PI-HBr (2 x 300mg tablets) a total of five doses

Trial Locations (1)

85032

Pulmonary Associates, Phoenix

Sponsors

Lead Sponsor

Spero Therapeutics

Collaborators (1)

Clinartis
All Listed Sponsors
collaborator

Clinartis

INDUSTRY

lead

Spero Therapeutics

INDUSTRY

NCT04710407 - Study to Assess the Intrapulmonary Pharmacokinetics of SPR859 by Comparing the Plasma, Epithelial Lining Fluid (ELF), and Alveolar Macrophages (AM) Concentrations Following the Oral Administration of Five Doses of SPR994 in Healthy, Nonsmoking Volunteers | Biotech Hunter | Biotech Hunter